Hasil Pencarian  ::  Simpan CSV :: Kembali

Hasil Pencarian

Ditemukan 3 dokumen yang sesuai dengan query
cover
Jamaluddin M
"ABSTRAK
Tesis ini menilai efikasi dan toksisiti Erlotinib/Gefitinib sebagai terapi lini kedua
pada pasien KPKBSK yang mengalami progresifitas. Ini adalah sebuah penelitian
kohor retrospektif antara tahun 2009 sampai 2013 dari rekam medis pasien
KPKBSK yang mengalami progresifitas. Respons (subjektif, semisubjektif dan
objektif) dievaluasi setiap bulan. Toksisiti dinilai setiap minggu sejak pemberian
Erlotinib/Gefitinib berdasarkan kriteria WHO. Hasil evaluasi respons objektif,
tidak ada pasien yang memberikan respons komplit. Best overall response rate
dari 31 pasien, 48,8% menetap, 22,6% perburukan,12,9% respons sebagian dan
6,5% tidak dinilai/inevaluable. Pada penilaian respons semisubjektif didapatkan
19.4% peningkatan berat badan, 51,6% penurunan berat badan dan 29,0%
menetap. Waktu tengah tahan hidup mencapai 18 bulan, rerata masa tahan hidup
1 tahunan 80,6% dan masa tahan hidup keseluruhan 6,50%. Data menunjukkan
tidak ada timbul toksisiti hematologi berat (grade ¾) dan data penilaian toksisiti
non hematologi sangat jarang timbul toksisiti berat (grade ¾). Efikasi monoterapi
EGFR-TKI (Erlotinib/Gefitinib) cukup tinggi dengan toksisiti yang ditimbulkan
tidak berat. Dengan demikian Erlotinib/Gefitinib sebagai terapi lini kedua cukup
baik.ABSTRACT This thesis assesses the efficacy and toxicity of Erlotinib/Gefitinib as a second
line therapy in NSCLC patients. This is a retrospective cohort study between 2009
and 2013 from the medical records of patients who experienced progression
NSCLC. Therapeutic response was evaluated every month. Toxicity assessed
every month since giving Erlotinib/Gefitinib according to WHO?s criteria. Results
of objective response evaluation none of the patients complete response. Best
overall response rate of 31 patients with the most stable response are 48.8%. Most
semisubjective response obtained are 51.6% weight loss. The middle survival time
reached 18 month, the mean 1 year survival time are 80.6% and a 6.50% overall
survival. The data showed no hematologic toxicity arise severe (grade ¾) and
non-hematological toxicity very rarely arise severe toxicity. The efficacy of EGFR
TKI monotherapy (Erlotinib/Gefitinib) is high enough with toxicity cause not
severe. Thus Erlotinib/Gefitinib as second-line therapy is quite good. ;This thesis assesses the efficacy and toxicity of Erlotinib/Gefitinib as a second
line therapy in NSCLC patients. This is a retrospective cohort study between 2009
and 2013 from the medical records of patients who experienced progression
NSCLC. Therapeutic response was evaluated every month. Toxicity assessed
every month since giving Erlotinib/Gefitinib according to WHO?s criteria. Results
of objective response evaluation none of the patients complete response. Best
overall response rate of 31 patients with the most stable response are 48.8%. Most
semisubjective response obtained are 51.6% weight loss. The middle survival time
reached 18 month, the mean 1 year survival time are 80.6% and a 6.50% overall
survival. The data showed no hematologic toxicity arise severe (grade ¾) and
non-hematological toxicity very rarely arise severe toxicity. The efficacy of EGFR
TKI monotherapy (Erlotinib/Gefitinib) is high enough with toxicity cause not
severe. Thus Erlotinib/Gefitinib as second-line therapy is quite good. "
Fakultas Kedokteran Universitas Indonesia, 2015
SP-PDF
UI - Tugas Akhir  Universitas Indonesia Library
cover
Hapsari Retno Dewanti
"Latar Belakang: Kanker paru menjadi penyebab kematian utama akibat keganasan pada laki-laki sebesar 31% dan perempuan sebesar 27%. Pada pasien adenokarsinoma paru dengan mutasi pada exon 20 T790M memberikan respons yang buruk terhadap terapi EGFR-TKI generasi pertama maupun generasi kedua.
Tujuan: Mengetahui profil serta angka tahan hidup 1 tahun pasien kanker paru jenis Adenokarsinoma dengan mutasi exon 20 T790M primer.
Metode: Penelitian menggunakan desain kohort terhadap pasien-pasien adenokarsinoma paru stadium IV dengan mutasi exon 20 T790M primer dari bulan September 2015 sampai Desember 2017 di RSUP Persahabatan. Variabel yang diteliti adalah karakteristik klinis dan angka kesintasanberdasarkan kurva Kaplan Meier. Hasil analisis dinyatakan berbeda bermakna apabila nilai p<0,05.
Hasil: Didapatkan 27 subjek penelitian dengan rerata usia 58,5 tahun dan berjenis kelamin laki-laki (70,6%). Keluhan utama berupa sesak napas (73,5%) dan nyeri dada (55,9%). Mutasi genetik tunggal pada Exon 20 T790M (64,7%), sedangkan mutasi Exon 20 T790M dengan Exon 21 L858R (11,8%) dan mutasi Exon 20 T790M dengan 21 L861Q (8,8%). Organ target metastasis adalah efusi pleura (73,5%), tulang (26,5%) dan otak (20,6%). Angka kesintasan 360 dan 990 hari sebesar 35% dan 20% dengan median kesintasan sebesar 213 hari.
Kesimpulan: Mutasi exon 20 T790M pada adenokarsinoma paru memegang peranan penting terhadap kesintasan dan prediktor responsterhadap terapi yang diberikan.

Background: Lung cancer causes mortality in men (31%) and in women (27%). Lung adenocarcinoma patients with exon 20 T790Mepidermal growth factor receptor(EGFR) mutation showed poor response to the first generation and second generation of EGFR tyrosine kinase inhibitor (TKI) therapy.
Purpose: This study aims to reveal the characteristics and one year survival rate of lung adenocarcinoma patients with primary exon 20 T790M EGFR mutations treated at Persahabatan Hospital Jakarta, Indonesia.
Methods: The cohort study involved patients with primary exon 20 T790M EGFR mutation between September 2015 to December 2017 in Persahabatan Hospital Jakarta, Indonesia. The survival rate was observed from Kaplan Meier estimator curve and was statistically analyzed.
Results: There were 27 subjects with mean age of 58.5 years and were predominated male (70.6%). The most common chief complaints were shortness of breath (73.5%) and chest pain (55.9%). The EGFR mutations detected were exon 20 T790M (64.7%), exon 20 T790M with exon 21 L858R (11.8%) and exon 20 T790M with exon 21 L861Q (8.8%). Metastatic target organs were pleural effusions (73.5%), bone (26.5%) and brain (20.6%). Survival rate of 360 and 990 days was 35% and 20% respectively with median survival rate was 213 days.
Conclusion: Exon 20 T790M EGFR mutation in lung adenocarcinoma was revealed to be an important factor in survival and in predicting response to EGFR TKI chemotherapy.
"
Jakarta: Fakultas Kedokteran Universitas Indonesia, 2018
SP-Pdf
UI - Tugas Akhir  Universitas Indonesia Library
cover
Mario Reggynal
"Latar belakang: Tumor mediastinum merupakan salah satu jenis tumor yang jarang ditemukan dengan variasi klinis yang luas dan histopatologi yang berbeda. Berbagai data seperti usia, jenis kelamin, pemeriksaan radiologi dan penanda tumor harus digabungkan untuk menentukan kemungkinan diagnosis pada pasien. Penanda tumor wajib diperiksa pada kasus tumor mediastinum sehingga pendekatan diagnosis dapat dilakukan dengan lebih baik. Peneliti akan menggunakan berbagai data seperti karakteristik pasien, pemeriksaan laboratorium, radiologis dan penanda tumor  untuk membantu memperoleh prediksi diagnosis jenis tumor mediastinum. Metode: Penelitian ini menggunakan data sekunder dari rekam medis. Semua pasien dengan diagnosis tumor mediastinum berdasarkan hasil CT scan yang dilakukan biopsi. Data histopatologi jaringan didapat dari laboratorium Patologi Anatomi Rumah Sakit Rujukan Respirasi Nasional Persahabatan. Data usia, jenis kelamin, radiologis, hasil laboratorium dan penanda tumor akan digunakan untuk mengetahui karakteristik setiap jenis tumor. Dilakukan analisis bivariat dan multivariat untuk menentukan variabel yang berpengaruh dan sistem penghitungan skor berdasarkan data tersebut. Hasil: Sebanyak 174 subjek memenuhi kriteria inklusi dengan usia rata-rata 29 tahun, lebih banyak pada laki-laki (67,8%), yang paling banyak adalah limfoma mediastinum (41,4%), berlokasi di anterior (75,9%), tidak memiliki pembesaran KGB (78,7%) dan tidak menginfiltrasi organ sekitarnya (58%). Sistem penghitungan skor yang tertinggi terdapat pada jenis limfoma mediastinum tetapi hanya menunjukkan akurasi sebesar 59%. Kesimpulan: Secara statistik tidak ada sistem penghitungan skor prediksi yang mempunyai kekuatan yang baik karena tumor mediastinum mempunyai kemiripan berdasarkan karakteristik pasien dan bentuk tumor sehingga sulit dibuat suatu sistem penghitungan skor.

Background: Mediastinal tumors are tumors that rarely found compared to other types of tumors. These tumors have many clinical variations with different histopathologies. Various data such as clinical condition, age, gender, radiological examination and tumor markers must be combined to determine the possibility of diagnosis in the patient. Tumor markers must be checked in all cases of mediastinal tumors so that a better diagnostic approach can be taken. This research will use that data to obtain scoring sytsem for the diagnosis of mediastinal tumors. Hopefully this scoring system can help doctors to make a better diagnosis in case of mediastinal tumors. Method: This research used secondary data from medical records. All patients with a diagnosis of mediastinal tumor based on CT scan results performed biopsy. Histopathology data was obtained from the Anatomical Pathology laboratory in the Persahabatan Hospital National Respiratory Center. Age, gender, radiology, laboratory results and tumor markers will be used to determine the characteristics of each type of tumor. Bivariate and multivariate analyzes were carried out to determine the significantly variables and a scoring system based on this data. Results: A total of 174 subjects met the inclusion criteria with an average age 29 years, more males (67.8%), the most common tumor was mediastinal lymphoma (41.4%), located anteriorly (75.9%), did not have lymph node enlargement (78.7%) and did not infiltrate surrounding organs (58%). The highest score of scoring system is for mediastinal lymphoma but only shows an accuracy of 59%. Conclusion: Statistically, there is no specific prediction score calculation system that has good power because mediastinal tumors are similar based on patient characteristics and tumor shape, making it difficult to create a scoring system."
Jakarta: Fakultas Kedokteran Universitas Indonesia, 2024
SP-pdf
UI - Tugas Akhir  Universitas Indonesia Library